FLOW CYTOMETRIC ANALYSIS OF TUMOR INFILTRATING LYMPHOCYTES IN BREAST-CANCER

被引:82
作者
WHITFORD, P
MALLON, EA
GEORGE, WD
CAMPBELL, AM
机构
[1] UNIV GLASGOW,DEPT BIOCHEM,GLASGOW G11 6NT,SCOTLAND
[2] WESTERN INFIRM & ASSOCIATED HOSP,DEPT SURG,GLASGOW G11 6NT,SCOTLAND
[3] WESTERN INFIRM & ASSOCIATED HOSP,DEPT PATHOL,GLASGOW G11 6NT,SCOTLAND
关键词
D O I
10.1038/bjc.1990.419
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
In 31 patients with carcinoma of the breast the phenotype and activation status of tumour infiltrating lymphocytes (TILs) was analysed by flow cytometry. The predominant cells, in all patients, were T lymphocytes and in the majority of cases CD8 + (cytotoxic/suppressor) T lymphocytes were present in greater numbers than CD4+ (helper) T lymphocytes. There was no relationship between the degree of lymphocytic infiltration and either tumour stage or grade but there appeared to be an inverse correlation with the levels of oestrogen receptor (ER) in the tumour (p<0. 01). Both populations of T cells had significantly higher numbers of cells carrying HLA DR (class II major histocompatibility antigen) than the equivalent populations in peripheral blood from the same patient group (P< 0. 001). The transferrin receptor was found on similar numbers of CD8 + T cells in peripheral blood and among the tumour infiltrating lymphocytes while more of the CD4 + T cells infiltrating the tumour were found to carry this receptor (P = 0. 034). The Tac (CD 25) antigen was also on similar numbers of CD8 + T cells from both peripheral blood and the tumour but was on fewer of the CD4+ T cells in the tumour with respect to peripheral blood (P = 0. 029). In both TILs and blood lymphocytes, the Tac antigen was consistently present on greater numbers of CD4 + T lymphocytes than on the CD8+ T lymphocytes (P< 0. 001) and as this is a component of the interleukin 2 (IL-2) receptor this may be of relevance to the use of IL-2 in TIL cancer therapy. © Macmillan Press Ltd., 1990.
引用
收藏
页码:971 / 975
页数:5
相关论文
共 42 条
[1]  
AN T, 1987, AM J PATHOL, V128, P52
[2]  
BELLDEGRUN A, 1988, CANCER RES, V48, P206
[3]  
BENEZRA J, 1987, CANCER, V59, P2037, DOI 10.1002/1097-0142(19870615)59:12<2037::AID-CNCR2820591212>3.0.CO
[4]  
2-G
[5]  
BERG JW, 1959, CANCER, V12, P714, DOI 10.1002/1097-0142(195907/08)12:4<714::AID-CNCR2820120414>3.0.CO
[6]  
2-B
[7]  
BHAN AK, 1983, J NATL CANCER I, V71, P507
[8]  
BILIK R, 1989, CANCER IMMUNOL IMMUN, V28, P143
[9]  
BLACK MM, 1955, SURG GYNECOL OBSTET, V100, P543
[10]   HISTOLOGICAL GRADING AND PROGNOSIS IN BREAST CANCER - A STUDY OF 1409 CASES OF WHICH 359 HAVE BEEN FOLLOWED FOR 15 YEARS [J].
BLOOM, HJG ;
RICHARDSON, WW .
BRITISH JOURNAL OF CANCER, 1957, 11 (03) :359-&